Fate therapeutics reports third quarter 2023 financial results and business updates

Phase 1 study open for enrollment of ft522 adr-armed, cd19-targeted car nk cell program for b-cell lymphoma; dose escalation designed to assess 3-dose treatment schedule with and without conditioning chemotherapy

FATE Ratings Summary

FATE Quant Ranking